REG - Synairgen plc - Data Presented at ESWI Influenza Conference

SynairgenAnnouncement

08/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211208:nRSH8998Ua&default-theme=true

RNS Number : 8998U  Synairgen plc  08 December 2021

 

Press Release

 

Synairgen plc

('Synairgen' or the 'Company')

Synairgen Presents In Vitro Potency Data for Interferon Beta Against
SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at
the 8(th) ESWI Influenza Conference

·    In vitro data demonstrate antiviral activity of SNG001 against
multiple variants of SARS-CoV-2

·    Clinical biomarker data show inhaled SNG001 stimulates lung antiviral
responses

 

Southampton, UK - 8 December 2021: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, a formulation for inhalation containing the
broad-spectrum antiviral protein interferon beta for the treatment of severe
viral lung infections, has presented in vitro and clinical data demonstrating
antiviral activity for SNG001 in a poster and an oral presentation
respectively at the 8(th) European Scientific Working Group in Influenza
(ESWI) Influenza Conference, which was held virtually 4-7 December, 2021.

In the poster session, Synairgen presented in vitro data demonstrating that
SNG001, our formulation of the naturally-occurring antiviral protein
interferon beta, potently reduced virus to undetectable levels in cells
infected with SARS-CoV-2 including the Alpha, Beta and Gamma variants of
concern (VOC), at concentrations that are readily achievable following inhaled
delivery of interferon beta.

"This study demonstrated potent antiviral activity of SNG001 against
SARS-CoV-2 including Alpha, Beta and Gamma variants, which is important given
the continuing emergence and global spread of variants of concern," Phillip
Monk, Ph.D., Synairgen Chief Scientific Officer, commented.

Synairgen is investigating the in vitro activity of SNG001 against the Delta
and Omicron variants of SARS-CoV-2 and will make data available as soon as
possible.

In a separate oral session on 6 December, Dr Monk presented data showing that
inhaled SNG001 significantly increased interferon beta-dependent antiviral
biomarkers in the lungs of asthma and chronic obstructive pulmonary disease
(COPD) patients enrolled in Phase 2 trials.

"SNG001 is an investigational drug currently in Phase 3 trials, with the first
data read out early in 2022, and contains the essential antiviral protein
interferon beta, a protein that 'switches on' antiviral defences. Interferon
beta production by lung cells is suppressed by the SARS-CoV-2 virus. We
presented data showing that SNG001 activates the lungs' antiviral defences for
24 hours after a dose has been delivered, supporting our once-a-day dosing
schedule," Dr Monk added.

 

 

 

Details of the two ESWI presentations are as follows:

Poster Presentation:

Title:               Interferon beta has potent antiviral
activity against SARS-CoV-2 including variants of concern

Abstract:        269

Vero E6 cells, a cell line that is widely used in virology studies, were
pre-treated with SNG001 16 hours before, and re-treated with SNG001 after,
infection with 'Wuhan-like' SARS-CoV-2, Alpha, Beta or Gamma variants. The
presence of viral protein-positive cells was determined 20 hours
post-infection by immunostaining.

The poster included the following data:

·    SNG001 potently reduced virus to undetectable levels following
infection of cells with 'Wuhan-like' SARS-CoV-2, Alpha, Beta or Gamma
variants.

·    SNG001 achieved 99% inhibition (IC99) at concentrations of 5.4, 17.7,
11.0 and 7.9 IU/mL respectively.

The poster presentation is available on the Synairgen website
(https://www.synairgen.com/umbraco/Surface/Download/GetFile?cid=b13a246f-a9fc-4e7e-aac2-622208c3ac71)
.

Oral Presentation:

Title:               Local delivery of interferon beta (SNG001)
by inhalation upregulates lung antiviral biomarkers

Abstract:        270

Sputum samples were collected from patients in two Phase 2 studies of SNG001:
SG005 (NCT01126177 (https://clinicaltrials.gov/ct2/show/NCT01126177) ) in
patients with asthma, and SG015 (NCT03570359
(https://clinicaltrials.gov/ct2/show/NCT03570359) ) in patients with COPD.
Gene expression of IFN-β-dependent antiviral biomarkers, MX1 and OAS1, in
cells in the sputum samples were measured by RT-qPCR.

The presentation included the following data:

·    Inhaled SNG001 significantly increased levels of interferon
beta-dependent antiviral biomarkers in the lungs of both patient populations
compared with pre-treatment levels.

·    Biomarker responses were similar in younger asthma patients and older
COPD patients at the same dose.

·    SNG001 was well tolerated.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No. 596/2014 ('MAR').

 

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Brooke.Clarke@synairgen.com (mailto:Brooke.Clarke@synairgen.com)

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

synairgen@consilium-comms.com (mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com (mailto:MConway@MKCStrategies.com)

Tel: +1 516-606-6545

 

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery,
development and commercialisation. The Company's primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially
the first host-targeted, broad-spectrum antiviral treatment delivered directly
into the lungs. SNG001 has been granted Fast Track status from the US Food and
Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent
Public Health study by the UK's National Institute for Health Research (NIHR).
Synairgen's Phase 3 clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase 2 trial in hospitalised
COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of
recovery to 'no limitation of activities' versus placebo.(1)

Founded by University of Southampton Professors Sir Stephen Holgate, Donna
Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG).
For more information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com) .

(1)https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
(https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext)
 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBBDDSDGDGBR